All the news Showing 8 of 8 articles from: CROI 2014Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Interferon-free regimens Interferon-free BMS combo cures 90% of genotype 1 hepatitis C Liz Highleyman / 27 March 2014 An all-oral regimen of daclatasvir, asunaprevir and BMS-791325 – without interferon or ribavirin – led to sustained response in approximately 90% of people with hepatitis C virus (HCV) who had not previously ... Interferon-free regimens Daclatasvir plus simeprevir are effective against hepatitis C genotype 1b Liz Highleyman / 25 March 2014 An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85 to 95% of people with hepatitis C genotype 1b, but this combination did not work ... Interferon-free regimens Merck combination suppresses HCV in mono-infected and co-infected patients Liz Highleyman / 25 March 2014 An all-oral combination of the hepatitis C virus (HCV) protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people with HIV and HCV co-infection and ... Triple therapy Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection Keith Alcorn / 21 March 2014 The hepatitis C protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured hepatitis C in nearly three-quarters of people with genotype 1 hepatitis C virus (HCV) and HIV co-infection in ... Interferon-free regimens Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients Liz Highleyman / 17 March 2014 An interferon-free regimen of sofosbuvir plus ribavirin for 24 weeks led to sustained response in three-quarters of previously untreated people with genotype 1 hepatitis C and HIV co-infection in the PHOTON-1 study, and in ... Treatment for people living with HIV and HCV Simeprevir cures almost 80% of first-time co-infected hepatitis C patients Keith Alcorn / 14 March 2014 The next-generation hepatitis C protease inhibitor simeprevir cured almost 80% of previously untreated people with hepatitis C and HIV co-infection when used in combination with pegylated interferon and ribavirin, Prof. Doug Dieterich of ... Interferon-free regimens AbbVie '3D' combination cures 99% of genotype 1b hepatitis C Keith Alcorn / 14 March 2014 A 12-week triple combination of direct-acting antivirals developed by AbbVie cured at least 99% of previously untreated people with genotype 1b hepatitis C infection, Prof. Rajendar Reddy of the University of Pennsylvania Hospital ... Interferon-free regimens Six-week oral treatment can cure hard-to-treat hepatitis C patients Liz Highleyman / 12 March 2014 Interferon- and ribavirin-free treatment using sofosbuvir, ledipasvir and a third direct-acting drug for as little as six weeks can cure most previously untreated people with genotype 1 hepatitis C virus (HCV), including those ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive